Incyte Corp. (INCY)

63.16
0.81 1.30
NASDAQ : Health Technology
Prev Close 62.35
Open 62.61
Day Low/High 62.35 / 63.93
52 Wk Low/High 61.30 / 140.11
Volume 2.05M
Avg Volume 2.22M
Exchange NASDAQ
Shares Outstanding 211.80M
Market Cap 14.43B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These Stocks Were Hit Hardest in Friday's Selloff

These Stocks Were Hit Hardest in Friday's Selloff

China's response to U.S. tariffs has markets tanking Friday, eating into the gains from a mostly positive week.

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte And Merck Provide Update On Phase 3 Study Of Epacadostat In Combination With KEYTRUDA® (pembrolizumab) In Patients With Unresectable Or Metastatic Melanoma

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252...

Incyte Targeted Therapy And Immuno-Oncology Portfolio To Be Featured In 15 Abstracts At The AACR Annual Meeting 2018

Incyte Targeted Therapy And Immuno-Oncology Portfolio To Be Featured In 15 Abstracts At The AACR Annual Meeting 2018

Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago,...

The New #21 Most Shorted Nasdaq 100 Component: Incyte

The New #21 Most Shorted Nasdaq 100 Component: Incyte

The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

(Photo: Business Wire)

(Photo: Business Wire)

Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURORDIS), and other rare disease health organizations and advocates in recognizing...

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 38 th Annual Health Care Conference on Tuesday,...

Incyte Reports 2017 Fourth-Quarter And Year-End Financial Results, Provides 2018 Financial Guidance And Updates On Key Clinical Programs

Incyte Reports 2017 Fourth-Quarter And Year-End Financial Results, Provides 2018 Financial Guidance And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 fourth-quarter and year-end financial results, highlighting both strong growth in total revenue and the significant progress being made across the product portfolio.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 2018 RBC Capital Markets Global Healthcare Conference on Wednesday, February 21, 2018 at 11:00 am (ET) in New York.

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Updates Conference Call Time To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today an update to the conference call and webcast time for its fourth quarter and year end 2017 financial results to 8:00 a.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte To Report Fourth Quarter And Year-End Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year end 2017 financial results conference call and webcast for 10:00 a.

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer By TRC Capital Corporation

Incyte Corporation (Nasdaq:INCY) today announced that it received notice of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to 1,500,000 shares of Incyte's common stock at a price of $88.

Incyte Moves Up In Analyst Rankings, Passing Fidelity National Information Services

Incyte Moves Up In Analyst Rankings, Passing Fidelity National Information Services

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #79 spot from Fidelity National Information Services Inc , according to ETF Channel. Below is a chart of Incyte Corporation versus Fidelity National Information Services Inc plotting their respective rank within the S&P 500 over time (INCY plotted in blue; FIS plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte And Syros Announce Global Target Discovery And Validation Collaboration Focused On Myeloproliferative Neoplasms

Incyte Corporation (NASDAQ:INCY) and Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 36 th Annual J.

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Verisk Analytics

Incyte Becomes #40 Most Shorted Nasdaq 100 Component, Replacing Verisk Analytics

The most recent short interest data has been released for the 11/30/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Four-Year Phase 3 Data Analysis Shows Durability Of Response Of Jakafi® (ruxolitinib) In Patients With Polycythemia Vera

Four-Year Phase 3 Data Analysis Shows Durability Of Response Of Jakafi® (ruxolitinib) In Patients With Polycythemia Vera

Incyte Corporation (Nasdaq:INCY) today announced new 208-week (4-year) follow-up data from the ongoing, global, multi-center, open-label Phase 3 RESPONSE study of Jakafi ® (ruxolitinib) comparing the efficacy and...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVH, FBIZ, FLWS, NWSA, RPM Downgrades: EQS, FRAN, FUNC, GVP, INCY, MPAA, OXBR, PCTY, SNFCA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Incyte Announces Initiation Of Pivotal Clinical Trial Of Ruxolitinib (Jakafi®) For The Treatment Of Essential Thrombocythemia

Incyte Announces Initiation Of Pivotal Clinical Trial Of Ruxolitinib (Jakafi®) For The Treatment Of Essential Thrombocythemia

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib (Jakafi ®) compared to anagrelide for the treatment of patients with essential...

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Jim Cramer highlights Apache, Incyte, Prudential, and ON Semiconductor in the Lightning Round.

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Jim Cramer says the playing field is all digital, and companies need the best technology when competitors like Amazon are both enemy and ally at the same time.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated With Baricitinib Reported Greater Improvements In Pain Compared To Adalimumab Or Placebo

ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated With Baricitinib Reported Greater Improvements In Pain Compared To Adalimumab Or Placebo

- Post-hoc analysis presented at ACR/ARHP shows pain improvement was consistent regardless of a patient's baseline pain severity

More Than 30 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 59th Annual ASH Meeting

More Than 30 Abstracts Highlighting Data From Incyte's Portfolio Accepted For Presentation At The 59th Annual ASH Meeting

Incyte Corporation (Nasdaq:INCY) announces that more than 30 abstracts including data from its clinical development programs for Jakafi ® (ruxolitinib), JAK1, PI3Kd, PIM and BRD will be presented at the upcoming...

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Reports 2017 Third-Quarter Financial Results And Updates On Key Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reports 2017 third-quarter financial results, highlighting 38 percent year-on-year growth in product-related revenue, driven by increased sales of Jakafi ® (ruxolitinib) in the U.

TheStreet Quant Rating: D (Sell)